Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Megadott ok: The study was stopped due to exhaustion of funding. No additional financial support could be obtained to continue study operations as planned.
Key facts
- Where
- Atlanta, Aurora, Boston, Buffalo, Charlotte, Chicago, Cleveland, Columbus, Duarte, Miami, Nashville, New York, San Francisco, Seattle, Stanford és Tampa, Egyesült ÁllamokSee the 18 sites
Where in Egyesült Államok
- Northside HospitalAtlanta, Egyesült ÁllamokNo longer taking part
- University of ColoradoAurora, Egyesült ÁllamokNo longer taking part
- Dana-Farber Cancer InstituteBoston, Egyesült ÁllamokNo longer taking part
- Massachusetts General HospitalBoston, Egyesült ÁllamokNo longer taking part
- Roswell Park Comprehensive Cancer CenterBuffalo, Egyesült ÁllamokNo longer taking part
- Levine Cancer InstituteCharlotte, Egyesült ÁllamokNo longer taking part
- University of Chicago MedicineChicago, Egyesült ÁllamokNo longer taking part
- Cleveland ClinicCleveland, Egyesült ÁllamokNo longer taking part
- The Ohio State University Comprehensive Cancer CenterColumbus, Egyesült ÁllamokNo longer taking part
- City of HopeDuarte, Egyesült ÁllamokNo longer taking part
- University of MiamiMiami, Egyesült ÁllamokNo longer taking part
- Vanderbilt University Medical CenterNashville, Egyesült ÁllamokNo longer taking part
- Memorial Sloan-Kettering Cancer CenterNew York, Egyesült ÁllamokNo longer taking part
- New York - Presbyterian - Weill Cornell Medical CenterNew York, Egyesült ÁllamokNo longer taking part
- University of California San FranciscoSan Francisco, Egyesült ÁllamokNo longer taking part
- Fred Hutchinson Cancer CenterSeattle, Egyesült ÁllamokNo longer taking part
- Stanford UniversityStanford, Egyesült ÁllamokNo longer taking part
- H Lee Moffitt Cancer CenterTampa, Egyesült ÁllamokNo longer taking part
Trial details
- Who runs it
- Center for International Blood and Marrow Transplant Research
- Trial code
- NCT05224661
- Record updated
- 2026. június 1.
- Original description
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).Read full original descriptionShow less
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
Inclusion: Provision of signed and dated informed consent form; Stated willingness to comply with all study procedures and availability for the duration of the study; Aged at least 18 years old at time of consent; Diagnosed with AML, in complete remission; Complete remission (CR) definition per local institutional criteria; CR with incomplete hematologic recovery (CRi) is not an exclusion criterion; MRD positivity is not an exclusion criterion; Undergoing alloHCT; Has a diagnostic AML specimen available.
Exclusion: Prior alloHCT; Diagnosis of acute promyelocytic leukemia.